ArticleBMC infectious diseases2025
Viral dynamics and factors associated with duration of COVID-19 positivity: evidence from the first-three epidemiological waves in Cameroon.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic Concordance of Two- and Three-Gene SARS-CoV-2 Molecular Assays in Cameroon: Implications for Efficient Pandemic Response in Low- and Middle-Income Countries.Journal of clinical laboratory analysis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
Abstract
backgroundCoronavirus 2019 (COVID-19) disease progression evidence and viral clearance time remain limited in tropical settings. Understanding this is crucial for public health control measures at community-level. We evaluated the viral dynamics of SARS-CoV-2 infection and factors associated with positivity duration in COVID-19 cases in Cameroon. MATERIAL AND
methodsWe conducted a retrospective cohort-study of SARS-CoV-2 positive cases from the first to third wave (March 2020-October 2021) in Yaounde-Cameroon. RT-PCR was carried out on the participants using nasopharyngeal swabs after every 7 days. SARS-CoV-2 positivity duration was evaluated from the first to last positive PCR-test before a negative result. Epi-info V.7.0 was used for data analyses with p < 0.05 considered statistically significant.
resultsA total of 282 participants were enrolled. The mean age was 41 ± 14 years, with male predominant (62.1%). We had 15.6% symptomatic participants of which 59% had cough. The overall median positivity duration was 15[IQR: 9-23] days with 15[IQR: 13-22] in the first, 17[IQR: 12-26] in the second and 9[IQR: 6-12] in the third wave (p < 0.0001). Positivity duration was significantly higher in males (16 versus 14 days, p = 0.03) those aged [35-45] years (16 days) followed by those ≥ 46 years(15 days); p = 0.008). Positivity duration was not affected by presence or absence of symptoms (p = 0.80). No significant correlation was found with viral load (r = 0.03; p = 0.61). Considering baseline (24.7 ± 7.2Ct) and last viral load (29.3 ± 5.9 Ct), the ΔCt (4.6 ± 1.3) and positivity duration (15 days) revealed a kinetic in viral decay of 0.3 ± 0.087 Ct/day.
conclusionsA median positivity duration of 15 days is in accordance with viral clearance around 2 weeks for optimal confinement at community-level. Men and/or the elderly stand at higher risk of prolonged infection. Given the viral decay (0.3 Ct daily), we suggest personalized confinement periods. The variability of positivity duration according to waves could be function of strains which could be a factor influencing positivity duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.